|
Product class:
|
Medicinal product with marketing authorization
|
|
Medicinal product class:
|
Human medicine
|
|
Name of medicinal product:
|
CINACALCET MYLAN
|
|
Active substances:
|
|
|
ATC code:
|
H05BX01
|
|
Dosage form:
|
film-coated tablet
|
|
Strength:
|
90mg
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
|
Summary of product characteristics (SPC):
|
|
|
Package information leaflet (PIL):
|
EST
|
|
Labelling:
|
|
|
Indication:
|
Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD)
on maintenance dialysis therapy.
Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or
vitamin D sterols, as appropriate (see section 5.1).
Reduction of hypercalcaemia in patients with:
• parathyroid carcinoma.
• primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium
levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not
clinically appropriate or is contraindicated.
|
|
Safety features:
|
Yes
|
|
Marketing authorization holder:
|
Mylan Pharmaceuticals Limited
|
|
Marketing authorization number:
|
EU/1/15/1054
|
|
Marketing authorization issued on:
|
November 23, 2015
|
|
Marketing authorization expires on:
|
Unlimited
|
|
Marketing authorization procedure type:
|
Centralised
|
|
Assessment report:
|
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
|
1703898
|
CINACALCET MYLAN
|
film-coated tablet
|
90mg 28TK
|
Prescription
|
|
|
|
|
|
|
1703900
|
CINACALCET MYLAN
|
film-coated tablet
|
90mg 30TK
|
Prescription
|
|
|
|
|
|
|
1820810
|
CINACALCET MYLAN
|
film-coated tablet
|
90mg 84TK
|
Prescription
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere